$PPCBJul 7, 2026, 8:30 AM ETAI processed
PPCB signs MOU with Avance to run Phase 1b first‐in‐human PRP trial
AI Summary
Propanc (PPCB) signed a Memorandum of Understanding with Avance Clinical to support the clinical delivery of its Phase 1b first‐in‐human trial of PRP in patients with advanced solid tumors. The planned study will evaluate safety, tolerability, PK, immunogenicity and preliminary activity; Avance highlights early‐phase oncology experience, adaptive dose‐escalation designs and use of Australian regulatory/tax advantages to accelerate start‐up.
Positives
- MOU establishes a partnership to advance PRP into a Phase 1b FIH clinical trial
- Avance Clinical brings extensive early‑phase oncology experience and global CRO capabilities
- Propanc’s Melbourne base and Australian regulatory/tax incentives could speed trial start‑up
Negatives
- MOU expresses intent and is not a finalized, binding trial contract
- No trial start date, enrollment size, funding or site details were provided
- Result relevance is early-stage — safety and efficacy remain unproven until trial data emerge
